Habbema JD - Search Results

1

Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands.

Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Bos AB, et al. Among authors: habbema jd. Int J Cancer. 2006 Nov 15;119(10):2372-5. doi: 10.1002/ijc.22114. Int J Cancer. 2006. PMID: 16858676

2

Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies.

Rebolj M, Bais AG, van Ballegooijen M, Boer R, Meerding WJ, Helmerhorst TJ, Habbema JD. Rebolj M, et al. Among authors: habbema jd. Int J Cancer. 2007 Oct 1;121(7):1529-35. doi: 10.1002/ijc.22838. Int J Cancer. 2007. PMID: 17565745

3

No increased risk for cervical cancer after a broader definition of a negative Pap smear.

Rebolj M, van Ballegooijen M, van Kemenade F, Looman C, Boer R, Habbema JD. Rebolj M, et al. Among authors: habbema jd. Int J Cancer. 2008 Dec 1;123(11):2632-5. doi: 10.1002/ijc.23803. Int J Cancer. 2008. PMID: 18767046

4

At what costs will screening with CT colonography be competitive? A cost-effectiveness approach.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD. Lansdorp-Vogelaar I, et al. Among authors: habbema jd. Int J Cancer. 2009 Mar 1;124(5):1161-8. doi: 10.1002/ijc.24025. Int J Cancer. 2009. PMID: 19048626 Free PMC article.

5

A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials.

Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. Lansdorp-Vogelaar I, et al. Among authors: habbema jd. Cancer. 2009 Jun 1;115(11):2410-9. doi: 10.1002/cncr.24256. Cancer. 2009. PMID: 19288570 Free PMC article.

6

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD. de Kok IM, et al. Among authors: habbema jd. J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1. J Natl Cancer Inst. 2009. PMID: 19571256

7

Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Lansdorp-Vogelaar I, et al. Among authors: habbema jd. J Natl Cancer Inst. 2009 Oct 21;101(20):1412-22. doi: 10.1093/jnci/djp319. Epub 2009 Sep 24. J Natl Cancer Inst. 2009. PMID: 19779203 Free PMC article.

8

Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?

de Kok IM, Habbema JD, van Rosmalen J, van Ballegooijen M. de Kok IM, et al. Among authors: habbema jd. Eur J Cancer. 2011 Feb;47(3):428-35. doi: 10.1016/j.ejca.2010.09.030. Eur J Cancer. 2011. PMID: 20971633

9

How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?

Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JD, van Ballegooijen M. Wilschut JA, et al. Among authors: habbema jd. Cancer. 2011 Sep 15;117(18):4166-74. doi: 10.1002/cncr.26009. Epub 2011 Mar 8. Cancer. 2011. PMID: 21387272 Free PMC article.

10

Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening.

Wilschut JA, Hol L, Dekker E, Jansen JB, Van Leerdam ME, Lansdorp-Vogelaar I, Kuipers EJ, Habbema JD, Van Ballegooijen M. Wilschut JA, et al. Among authors: habbema jd. Gastroenterology. 2011 Nov;141(5):1648-55.e1. doi: 10.1053/j.gastro.2011.07.020. Epub 2011 Jul 22. Gastroenterology. 2011. PMID: 21784045

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

469 results

Search Page

Filters